Intracellular targets: Current data on effectiveness and safety profile;Intrazelluläre Targets: Aktuelle Datenlage zu Wirksamkeit und Sicherheitsprofil

Zeitschrift fur Rheumatologie

Volumn 72, Issue 9, 2013, Pages 867-872

  Alten, R ^a  

^a Schlosspark Klinik   (Germany)

Author keywords

Intracellular targets; Janus kinases; Protein kinase inhibitors; Rheumatoid arthritis; Safety

Indexed keywords

TOFACITINIB;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRACELLULAR SIGNALING; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EVIDENCE-BASED MEDICINE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84888599553     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-013-1139-4     Document Type: Article

References (24)

1. Ahadieh S, Checchio T, Tensfeldt T et al (2012) Meta-analysis of mailignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. Arthritis Rheum 64(10/Suppl):S726
2. Askling J, Fahrbach K, Nordstrom B et al (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20:119-130
3. Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451-460
4. Cambier JC, Pleiman CM, Clark MR (1994) Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol 12:457-486
5. Fleischmann R, Cutolo M, Genovese MC et al (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64:617-629
6. Fleischmann R, Spencer-Green G, Fan F et al (2011) Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Arthritis Rheum:LB3
7. Ghoreschi K, Jesson MI, Li X et al (2011) Modulation of Innate and adaptive immune responses by tofacitinib (CP-690, 550). J Immunol 186:4234-4243
8. Kawalec P, Mikrut A, Wisniewska N et al (2013) The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol
9. Kremer JM, Bloom BJ, Breedveld FC et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 60:1895-1905
10. Kyttaris VC (2012) Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 6:245-250
11. Leonard WJ, O'shea JJ (1998) Jaks and STATs: biological implications. Ann Rev Immunol 16:293-322
12. O'shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161-170
13. O'shea JJ, Kontzias A, Yamaoka K et al (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72(Suppl 2):ii111-ii115
14. O'shea JJ, Laurence A, Mcinnes IB (2013) Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 9:173-182
15. Pfizer (2012) XELJANZ® (tofacitinib) tablets for oral administration. In: US prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx? id=959
16. Salgado E, Maneiro JR, Carmona L et al (2013) Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis
17. Scott LJ (2013) Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs 73:857-874
18. Van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508-519
19. Vanhoutte F, Mazur M, Namour F et al (2012) Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIa trial. Ann Rheum Dis 145
20. Weinblatt ME, Kavanaugh A, Genovese MC et al (2013) Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol 40:369-378
21. Wilkie WS, Schwieterman P (2012) Strategies for the management of rheumatoid arthritis. Orthopedics 35:125-130
22. Winthrop K, Park SH, Gul A et al (2012) Tuberculosis and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum 64(10 Suppl):S547
23. Winthrop K, Valdez H, Mortensen E et al (2012) Herpes zoster and tofacitinib therapiy in patients with rheumatoid arhritis. Arthritis Rheum 64(10 Suppl):S1051
24. Winthrop KL, Furst DE (2010) Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy. Ann Rheum Dis 69:1735-1737